MX2020009645A - Inhibidores de secrecion de proteinas basados en triazaciclododecansulfonamida ("tcd"). - Google Patents
Inhibidores de secrecion de proteinas basados en triazaciclododecansulfonamida ("tcd").Info
- Publication number
- MX2020009645A MX2020009645A MX2020009645A MX2020009645A MX2020009645A MX 2020009645 A MX2020009645 A MX 2020009645A MX 2020009645 A MX2020009645 A MX 2020009645A MX 2020009645 A MX2020009645 A MX 2020009645A MX 2020009645 A MX2020009645 A MX 2020009645A
- Authority
- MX
- Mexico
- Prior art keywords
- triazacyclododecansulfonamide
- tcd
- protein secretion
- based protein
- secretion inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 230000028327 secretion Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101100476756 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sec-61 gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Aquí se proporcionan inhibidores de la secreción de proteínas basados en triazaciclododecansulfonamida ("TCD"), tales como inhibidores de Sec61, métodos para su preparación, composiciones farmacéuticas relacionadas y métodos para usar los mismos. Por ejemplo, aquí se proporcionan compuestos de Fórmula (I): (ver Fórmula) y sales y composiciones farmacéuticamente aceptables que incluyen las mismas. Los compuestos descritos aquí pueden usarse, por ejemplo, en el tratamiento de enfermedades que incluyen inflamación y/o cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643931P | 2018-03-16 | 2018-03-16 | |
| US201962803704P | 2019-02-11 | 2019-02-11 | |
| PCT/US2019/022533 WO2019178510A1 (en) | 2018-03-16 | 2019-03-15 | Triazacyclododecansulfonamide ("tcd")-based protein secretion inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009645A true MX2020009645A (es) | 2020-10-08 |
Family
ID=66041635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009645A MX2020009645A (es) | 2018-03-16 | 2019-03-15 | Inhibidores de secrecion de proteinas basados en triazaciclododecansulfonamida ("tcd"). |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US11578055B2 (es) |
| EP (1) | EP3765447B1 (es) |
| JP (1) | JP2021518337A (es) |
| KR (1) | KR102838413B1 (es) |
| CN (1) | CN112262129B (es) |
| AU (1) | AU2019236248B2 (es) |
| BR (1) | BR112020018767A2 (es) |
| CA (1) | CA3093972A1 (es) |
| CL (1) | CL2020002398A1 (es) |
| CO (1) | CO2020012484A2 (es) |
| DK (1) | DK3765447T3 (es) |
| ES (1) | ES2953139T3 (es) |
| FI (1) | FI3765447T3 (es) |
| HR (1) | HRP20230804T1 (es) |
| HU (1) | HUE062455T2 (es) |
| IL (1) | IL277252B2 (es) |
| JO (1) | JOP20200233A1 (es) |
| LT (1) | LT3765447T (es) |
| MA (1) | MA52008A (es) |
| MX (1) | MX2020009645A (es) |
| MY (1) | MY203877A (es) |
| PE (1) | PE20210926A1 (es) |
| PH (1) | PH12020551493A1 (es) |
| PL (1) | PL3765447T3 (es) |
| PT (1) | PT3765447T (es) |
| RS (1) | RS64524B1 (es) |
| SA (1) | SA520420147B1 (es) |
| SG (1) | SG11202008841VA (es) |
| SI (1) | SI3765447T1 (es) |
| SM (1) | SMT202300247T1 (es) |
| TW (1) | TWI818962B (es) |
| WO (1) | WO2019178510A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199618A (zh) * | 2022-12-30 | 2023-06-02 | 深圳市江川医药技术有限公司 | 一种高产率高纯度合成氟哌啶醇杂质e的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663161A (en) * | 1995-02-17 | 1997-09-02 | The Research Foundation Of State University Of New York | Anti-viral triaza compounds |
| US5724868A (en) * | 1996-01-11 | 1998-03-10 | Buck Knives, Inc. | Method of making knife with cutting performance |
| WO2002080856A2 (en) * | 2001-04-06 | 2002-10-17 | University And Community College System Of Nevada On Behalf Of The University Of Nevada, Reno | Triaza compound immunoregulatory agents |
-
2019
- 2019-03-15 ES ES19715609T patent/ES2953139T3/es active Active
- 2019-03-15 HU HUE19715609A patent/HUE062455T2/hu unknown
- 2019-03-15 CN CN201980032763.5A patent/CN112262129B/zh active Active
- 2019-03-15 FI FIEP19715609.4T patent/FI3765447T3/fi active
- 2019-03-15 MA MA052008A patent/MA52008A/fr unknown
- 2019-03-15 LT LTEPPCT/US2019/022533T patent/LT3765447T/lt unknown
- 2019-03-15 JO JOP/2020/0233A patent/JOP20200233A1/ar unknown
- 2019-03-15 KR KR1020207029261A patent/KR102838413B1/ko active Active
- 2019-03-15 JP JP2020548935A patent/JP2021518337A/ja active Pending
- 2019-03-15 BR BR112020018767-4A patent/BR112020018767A2/pt not_active Application Discontinuation
- 2019-03-15 SI SI201930602T patent/SI3765447T1/sl unknown
- 2019-03-15 US US16/979,457 patent/US11578055B2/en active Active
- 2019-03-15 DK DK19715609.4T patent/DK3765447T3/da active
- 2019-03-15 SG SG11202008841VA patent/SG11202008841VA/en unknown
- 2019-03-15 IL IL277252A patent/IL277252B2/en unknown
- 2019-03-15 AU AU2019236248A patent/AU2019236248B2/en active Active
- 2019-03-15 EP EP19715609.4A patent/EP3765447B1/en active Active
- 2019-03-15 PL PL19715609.4T patent/PL3765447T3/pl unknown
- 2019-03-15 MX MX2020009645A patent/MX2020009645A/es unknown
- 2019-03-15 WO PCT/US2019/022533 patent/WO2019178510A1/en not_active Ceased
- 2019-03-15 HR HRP20230804TT patent/HRP20230804T1/hr unknown
- 2019-03-15 TW TW108108893A patent/TWI818962B/zh active
- 2019-03-15 SM SM20230247T patent/SMT202300247T1/it unknown
- 2019-03-15 CA CA3093972A patent/CA3093972A1/en active Pending
- 2019-03-15 PE PE2020002281A patent/PE20210926A1/es unknown
- 2019-03-15 PT PT197156094T patent/PT3765447T/pt unknown
- 2019-03-15 RS RS20230647A patent/RS64524B1/sr unknown
- 2019-03-15 MY MYPI2020004809A patent/MY203877A/en unknown
-
2020
- 2020-09-15 PH PH12020551493A patent/PH12020551493A1/en unknown
- 2020-09-16 CL CL2020002398A patent/CL2020002398A1/es unknown
- 2020-09-16 SA SA520420147A patent/SA520420147B1/ar unknown
- 2020-10-06 CO CONC2020/0012484A patent/CO2020012484A2/es unknown
-
2022
- 2022-05-11 US US17/741,989 patent/US20220402891A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| CO2020015758A2 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| JOP20190229A1 (ar) | مركبات تثبط بروتين mcl-1 | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| CL2021000627A1 (es) | Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular | |
| CO2020012484A2 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
| AR088845A1 (es) | Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel | |
| MX2019007950A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa. | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| AR114282A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”) | |
| EA202092185A1 (ru) | Ингибиторы секреции белка на основе триазациклододекансульфонамида ("tcd") |